Ratings LifeTech Scientific Corporation

Equities

1302

KYG548721177

Delayed Hong Kong S.E. Other stock markets 11:59:07 2024-05-02 pm EDT			5-day change	1st Jan Change
1.73 ^HKD	-3.35%		+7.45%	-26.38%

Apr. 11	Lifetech Scientific Buys Shares For Employee Incentive Scheme	MT
Apr. 04	Lifetech Scientific Unit Invests 340 Million Yuan in Structured Deposits	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
LIFETECH SCIENTIFIC CORPORATION	-24.26%	1.02B	-
THERMO FISHER SCIENTIFIC	+7.62%	219B	B
DANAHER CORPORATION	+6.70%	183B	B-
INTUITIVE SURGICAL, INC.	+11.94%	132B	B-
BOSTON SCIENTIFIC CORPORATION	+24.60%	106B	A-
SIEMENS HEALTHINEERS AG	-2.66%	62.09B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.88B	B+
EDWARDS LIFESCIENCES CORPORATION	+11.55%	50.8B	B+
AGILENT TECHNOLOGIES, INC.	-1.09%	40.64B	A
RESMED, INC.	+26.82%	31.59B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes